[go: up one dir, main page]

MX2009001962A - Acilanilidas substituidas y metodos de uso de las mismas. - Google Patents

Acilanilidas substituidas y metodos de uso de las mismas.

Info

Publication number
MX2009001962A
MX2009001962A MX2009001962A MX2009001962A MX2009001962A MX 2009001962 A MX2009001962 A MX 2009001962A MX 2009001962 A MX2009001962 A MX 2009001962A MX 2009001962 A MX2009001962 A MX 2009001962A MX 2009001962 A MX2009001962 A MX 2009001962A
Authority
MX
Mexico
Prior art keywords
methods
substituted acylanilides
disorder
acylanilides
substituted
Prior art date
Application number
MX2009001962A
Other languages
English (en)
Inventor
James T Dalton
Duane D Miller
Original Assignee
Univ Tennessee Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/033490 external-priority patent/WO2007027582A2/en
Application filed by Univ Tennessee Res Foundation filed Critical Univ Tennessee Res Foundation
Publication of MX2009001962A publication Critical patent/MX2009001962A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C07C255/51—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings containing at least two cyano groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona compuestos SARM y uso de los mismos para tratar una variedad de enfermedades o condiciones en un sujeto, incluyendo entre otros, enfermedad y/o trastorno de desgaste muscular o una enfermedad y/o trastorno relacionado con los huesos.
MX2009001962A 2006-08-24 2007-08-24 Acilanilidas substituidas y metodos de uso de las mismas. MX2009001962A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83966506P 2006-08-24 2006-08-24
PCT/US2006/033490 WO2007027582A2 (en) 2005-08-31 2006-08-28 Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US11/510,844 US20070066568A1 (en) 2005-08-31 2006-08-28 Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US90774907P 2007-04-16 2007-04-16
PCT/US2007/018686 WO2008024456A2 (en) 2006-08-24 2007-08-24 Substituted acylanilides and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009001962A true MX2009001962A (es) 2009-04-30

Family

ID=48170081

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001962A MX2009001962A (es) 2006-08-24 2007-08-24 Acilanilidas substituidas y metodos de uso de las mismas.

Country Status (19)

Country Link
US (3) US8080682B2 (es)
EP (2) EP3056483A1 (es)
JP (2) JP5345534B2 (es)
KR (2) KR101202240B1 (es)
CN (3) CN107007581A (es)
AR (1) AR062536A1 (es)
AU (1) AU2007287070C1 (es)
BR (1) BRPI0714526A2 (es)
CA (1) CA2660570C (es)
CY (1) CY1117817T1 (es)
DK (1) DK2054049T3 (es)
EA (1) EA016853B1 (es)
ES (1) ES2581765T3 (es)
HU (1) HUE029808T2 (es)
IL (3) IL197185A (es)
MX (1) MX2009001962A (es)
PL (1) PL2054049T3 (es)
PT (1) PT2054049E (es)
WO (1) WO2008024456A2 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445534B2 (en) * 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
BRPI0617117A2 (pt) * 2005-08-31 2011-07-12 Univ Tennessee Res Foundation tratamento de doença renal, queimaduras, ferimentos e danos na corda espinhal com moduladores seletivos de receptores de androgênio
US9844528B2 (en) * 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) * 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
CN107007581A (zh) * 2006-08-24 2017-08-04 田纳西大学研究基金会 取代的n‑酰基苯胺及其使用方法
US10010521B2 (en) * 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
SI2285364T1 (sl) 2008-05-07 2015-03-31 The Regents Of The University Of California Terapevtska regeneracija in obogatitev lubrikacije okularne površine
WO2010027743A1 (en) * 2008-08-25 2010-03-11 Alpha Synergy Development, Inc. Pharmaceutical compositions and methods for the treatment of dry eye
US20100130457A1 (en) * 2008-11-14 2010-05-27 Immune Control, Inc. Phenothiazine Derivatives for Treatment of Asthma
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
ES2689700T3 (es) * 2008-12-09 2018-11-15 Metabolic Technologies, Inc. Intervención nutricional para mejorar la función y resistencia muscular
US8870876B2 (en) * 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
CA2767942A1 (en) * 2009-03-12 2010-09-16 Viridis Biopharma Pvt Ltd. Method of use of vitamin k as energy enhancer in diverse disease states
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
CA2776950C (en) * 2009-10-09 2023-11-21 Nestec S.A. Use of isoflavones in the prevention or treatment of sarcopenia and muscle atrophy
JP2013516501A (ja) * 2010-01-11 2013-05-13 ジーティーエックス・インコーポレイテッド マイボーム腺機能障害を治療する方法
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
WO2011097496A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
AU2015200324C1 (en) * 2010-03-23 2016-12-15 University Of Tennessee Research Foundation SARMs and method of use thereof
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
KR20130063962A (ko) * 2011-12-07 2013-06-17 가천대학교 산학협력단 디아미노디페닐술폰을 포함하는 골량 저하 질환의 예방 또는 치료용 약학적 조성물
KR101875705B1 (ko) * 2011-12-07 2018-07-06 삼성전자주식회사 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물
WO2013134311A1 (en) * 2012-03-07 2013-09-12 Ligand Pharmaceuticals, Inc. Steroid hormone and cholesterol pathways as one unified homestatic system
BR112014027885B1 (pt) * 2012-05-09 2022-07-26 Icrom Spa Processo para a preparação de um pó a granel de brinzolamida estéril
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
CN108143728A (zh) 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
EP2893343B1 (en) 2012-09-07 2019-11-20 The Governors of the University of Alberta Methods for diagnosis of inflammatory liver disease
WO2014144907A1 (en) * 2013-03-15 2014-09-18 Children's Medical Center Corporation Methods and compounds for the treatment of dystroglycanopathies
KR20160067225A (ko) * 2013-10-24 2016-06-13 유니버시티 오브 테네시 리서치 파운데이션 암 환자에서 근육 소모를 치료하는 선택적 안드로겐 수용체 조절물질 및 화학치료제
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
IL255189B2 (en) 2015-04-29 2024-04-01 Radius Pharmaceuticals Inc A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
EP3349745B1 (en) 2015-09-16 2023-12-13 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for enhancing recovery from soft tissue trauma
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
CA3027563C (en) 2016-06-22 2024-07-02 Ellipses Pharma Ltd AR+ METHODS FOR BREAST CANCER TREATMENT
JP2020500198A (ja) * 2016-11-17 2020-01-09 サイトーＣｙｔｏｏ 骨格筋肥大誘発剤
CN106748884B (zh) * 2016-12-13 2021-08-20 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
WO2019027051A1 (ja) * 2017-08-03 2019-02-07 ソニー株式会社 コンタクトレンズおよび検出方法
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
CN109207724B (zh) * 2018-09-12 2020-12-29 哈尔滨工业大学（威海） 一种从含钒铬溶液中同时萃取分离钒铬的萃取溶剂及萃取方法
CN109761778A (zh) * 2018-12-10 2019-05-17 石家庄市度智医药科技有限公司 一种合成光学活性α-羟基丙酰胺衍生物的方法
CN111418558B (zh) * 2019-09-22 2021-09-28 山西大学 一种消融代谢性泌尿结石动物模型的构建方法
CA3166734A1 (en) * 2020-01-27 2021-08-05 Eirgen Pharma Ltd. Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease
EP4102971A4 (en) 2020-02-10 2024-05-01 Virox Technologies Inc. Antimicrobial compositions containing peroxyphthalic acid and/or salt thereof
WO2022006470A1 (en) 2020-07-01 2022-01-06 Vanderbilt University Methods of treatment for a kidney disease
WO2023215684A1 (en) * 2022-05-05 2023-11-09 The Trustees Of Indiana University Therapeutic strategies to manage facial contractures post injury
CN114796496B (zh) * 2022-05-09 2023-06-23 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 交感神经活化抑制剂和/或α1-肾上腺素能受体抑制剂在制备治疗干眼症的药物中的应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256096A (en) 1961-08-11 1966-06-14 Organic Nutrients Inc Anabolic stimulator as a poultry feed supplement
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US3949085A (en) 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US3865801A (en) 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US3946109A (en) 1973-08-08 1976-03-23 Ernst Kolb Animal feed composition containing certain vitamin combinations
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US4211781A (en) 1974-09-23 1980-07-08 Pfizer Inc. Process for the preparation of dustless quinoxaline-1,4-dioxide animal feed supplement premixes
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (en) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
US4447421A (en) 1980-05-08 1984-05-08 American Cyanamid Company Process for the preparation of medicated animal feed supplement
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
US4670249A (en) 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
US4837004A (en) 1985-10-18 1989-06-06 Eastman Kodak Company Rumen-stable pellets
US4904473A (en) 1986-06-23 1990-02-27 International Minerals & Chemical Corp. Ruminant feed antacid containing potassium, sodium and chlorine
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US4849447A (en) 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
DE68919213T2 (de) 1988-01-28 1995-05-11 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
ATE122357T1 (de) 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
US4977288A (en) 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US5030657A (en) 1989-10-23 1991-07-09 University Of Georgia Research Foundation, Inc. L-carnitine supplemented catfish diet
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
WO1995019770A1 (en) 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
CA2149496C (en) 1994-05-19 2006-12-19 Ronald Gebhard 11,21-bisphenyl-19-norpregnane derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20050038110A1 (en) 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU7604798A (en) 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (en) 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
US6022137A (en) 1998-04-29 2000-02-08 Buckeye Feed Mills, Inc. Conditioner for processing raw grain composition to produce pelletized feed
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
TR200102805T2 (tr) 1999-03-29 2002-04-22 F.Hoffmann-La Roche Ag Glikokinaz aktivatörleri
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
WO2001027622A1 (en) 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
AU1968601A (en) 1999-10-19 2001-04-30 Nobex Corporation Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
EP1224167A1 (en) 1999-10-27 2002-07-24 Nobex Corporation Resolution of intermediates in the synthesis of substantially pure bicalutamide
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
WO2001049709A1 (en) 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US6441197B1 (en) * 2000-01-20 2002-08-27 Daiichi Pure Chemicals Co., Ltd. Diaminofluorescein derivative
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
BR0111298A (pt) 2000-06-28 2005-05-10 Bristol Myers Squibb Co Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos
JP2002035743A (ja) * 2000-07-21 2002-02-05 Kurita Water Ind Ltd 軟水装置
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
DE60124322T2 (de) 2000-08-24 2007-05-31 University Of Tennessee Research Foundation, Knoxville Selektive modulatoren des androgenrezeptors und methoden zu deren verwendung
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
HRP20040588A2 (en) * 2001-12-06 2004-10-31 Gtx Inc Treating muscle wasting with selective androgen receptor modulators
CA2474168A1 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
CN1646115B (zh) 2002-02-07 2010-06-09 Gtx公司 Sarms在制备用于治疗良性前列腺增生的药物中的应用
EP1487458B1 (en) 2002-02-28 2011-11-16 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
CN1639110A (zh) * 2002-02-28 2005-07-13 田纳西大学研究基金会 卤代乙酰胺和叠氮化物取代的化合物及其使用方法
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
CA2512049A1 (en) 2002-12-30 2004-07-22 Purdue Research Foundation Method of treatment for central nervous system injury
US20050032750A1 (en) * 2003-01-22 2005-02-10 Steiner Mitchell S. Treating androgen deficiency in female (ADIF)-associated conditions with SARMS
GB0308335D0 (en) 2003-04-10 2003-05-14 Novartis Ag Organic compounds
ATE378047T1 (de) 2003-09-12 2007-11-15 Serono Lab Benzothiazol-derivate zur behandlung von diabetes
EP1673376A4 (en) * 2003-10-14 2010-06-23 Gtx Inc TREATMENT OF BONE DISEASES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
DE602005015962D1 (de) 2004-05-03 2009-09-24 Hoffmann La Roche Indolylderivate als liver-x-rezeptormodulatoren
ATE552235T1 (de) 2004-06-07 2012-04-15 Univ Tennessee Res Foundation Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür
CN101014327A (zh) 2004-07-14 2007-08-08 詹森药业有限公司 用于治疗雌激素相关α受体介导的疾病的亚芳基类物质
WO2006011141A2 (en) 2004-07-25 2006-02-02 Israel Aerospace Industries Ltd. Method and system for the acquisition of data and for the display of data
BRPI0617117A2 (pt) 2005-08-31 2011-07-12 Univ Tennessee Res Foundation tratamento de doença renal, queimaduras, ferimentos e danos na corda espinhal com moduladores seletivos de receptores de androgênio
US8796313B2 (en) 2005-11-01 2014-08-05 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
EP1951706A1 (en) 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
EP1962835A2 (en) 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
CN107007581A (zh) * 2006-08-24 2017-08-04 田纳西大学研究基金会 取代的n‑酰基苯胺及其使用方法
JP2013516501A (ja) * 2010-01-11 2013-05-13 ジーティーエックス・インコーポレイテッド マイボーム腺機能障害を治療する方法

Also Published As

Publication number Publication date
CN103251579A (zh) 2013-08-21
AR062536A1 (es) 2008-11-12
CN101528214A (zh) 2009-09-09
US8080682B2 (en) 2011-12-20
AU2007287070A1 (en) 2008-02-28
IL197185A (en) 2014-02-27
CN103251579B (zh) 2016-12-28
KR20110081906A (ko) 2011-07-14
PL2054049T3 (pl) 2016-11-30
WO2008024456A2 (en) 2008-02-28
HUE029808T2 (en) 2017-03-28
EP2054049B1 (en) 2016-04-13
KR101202240B1 (ko) 2012-11-16
EA200900345A1 (ru) 2009-08-28
IL197185A0 (en) 2009-12-24
AU2007287070B2 (en) 2012-07-05
IL244442A0 (en) 2016-04-21
CA2660570C (en) 2016-08-09
US20080076829A1 (en) 2008-03-27
US20130324602A1 (en) 2013-12-05
JP2013139472A (ja) 2013-07-18
AU2007287070C1 (en) 2013-02-14
DK2054049T3 (en) 2016-08-01
IL244442B (en) 2018-05-31
IL230759A0 (en) 2014-03-31
KR20090061010A (ko) 2009-06-15
JP5345534B2 (ja) 2013-11-20
ES2581765T3 (es) 2016-09-07
EP3056483A1 (en) 2016-08-17
CN107007581A (zh) 2017-08-04
US8846756B2 (en) 2014-09-30
WO2008024456A3 (en) 2008-07-03
IL230759A (en) 2016-03-31
JP5745560B2 (ja) 2015-07-08
EP2054049A2 (en) 2009-05-06
CA2660570A1 (en) 2008-02-28
KR101264820B1 (ko) 2013-05-22
PT2054049E (pt) 2016-06-02
US8426465B2 (en) 2013-04-23
CY1117817T1 (el) 2017-05-17
CN101528214B (zh) 2013-06-05
US20120136052A1 (en) 2012-05-31
BRPI0714526A2 (pt) 2013-04-30
EA016853B1 (ru) 2012-08-30
EP2054049A4 (en) 2010-12-29
JP2010501574A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
MX2009001962A (es) Acilanilidas substituidas y metodos de uso de las mismas.
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
EA011306B8 (ru) Избирательные модуляторы андрогеновых рецепторов и способы их применения
MX2009000715A (es) Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MY153198A (en) Inhibitors of protein aggregation
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
GT201200189A (es) Antagonistas de pcsk9
MX2009006252A (es) Sal de tanato de rasagilina.
IL201792A (en) Polyvalent polypeptides, anti-rank-l-directed substances for the treatment of irregularities and bone diseases
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
GB0410399D0 (en) The treatment of respiratory disease
GB0410398D0 (en) The treatment of respiratory disease
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
MX2010001303A (es) Compuestos terapeuticos.
UA98500C2 (en) Substituted acylanilides and methods of use thereof
TW200628168A (en) Use of organic compounds
UA96269C2 (uk) Інгібітори цистеїнпротеази та їх терапевтичне застосування

Legal Events

Date Code Title Description
FG Grant or registration